ARCHIVES

Lilly Made False Claims About Ralozifene Reducing Breast Cancer risk, Judge Rules

This article is from The Cancer Letter archive.

Vol. 25 No. 30 | July 30, 1999

Download PDF Visit The Full Archive

Related Articles

Improved Therapies For Cervical Cancer Said To Show Promise In Clinical Trials

March 26, 2004

FDA Blocks Nine More INDs; Cooperative Group Chairmen, DeVita Blast “Lack of Expertise”

January 7, 1977

FDA Accepts Advisory Committee’s Recommendations On NDA, Labeling

October 26, 1979

Schweiker Approves Transfer Of NTP’s NNCI Contribution To NIESH In FY’83

July 31, 1981

Gottlieb questions ODAC’s independence.

August 5, 2005

FDA Hears More Criticism On Cancer Drug Endpoints; Joint Conferences On Criteria Recommended

July 28, 1989